Good news! However, this early stage approach seems very technically involved and complicated.
"... researchers have reimagined the spleen as a viable site for islet transplantation, enabling long-term diabetes control without the burden of full immunosuppression. Nanoparticle-driven spleen remodeling allowed transplanted mouse, rat, and human islets to restore normal blood sugar in diabetic rodents and cynomolgus macaques. ...
In the study ... researchers engineered spleens with glucomannan-coated silica nanoparticles to create a vascularized, immunosuppressive environment for transplanted islets. ..."
From the editor's summary and abstract:
"Editor’s summary
Pancreatic islet transplantation is a promising approach for treating type 1 diabetes mellitus (T1DM) but can be beset by problems with engraftment or immunogenicity. Liu et al. used injection of immunomodulatory nanoparticles to remodel the extrahepatic spleens of T1DM mice into a more hospitable transplant site that supported the engraftment, vascularization, and function of transplanted allo- and xenogeneic islets. Proof-of-concept transplants of human islets into macaques on different degrees of immunosuppression further advocated for the feasibility of the approach. This study supports further safety and efficacy testing of the remodeled spleen as an islet transplant site for ameliorating insulin-deficient diabetes.
Abstract
Islet transplantation is a promising therapy for insulin-dependent diabetes. However, immune rejection and insufficient vascularization hinder the survival and function of transplanted islets.
Here, we show effective engraftment of vascularized and functional mouse and rat islets transplanted into biomaterial-remodeled spleens of nonimmunosuppressed rodents and human islets transplanted into the remodeled spleens of nonhuman primates (NHPs) on varying degrees of immunosuppression.
We found evidence that konjac glucomannan–modified silica nanoparticles (KSiNPs) remodeled the spleen into an extracellular matrix (ECM)–rich, immunosuppressive niche to support the survival of syngeneic or xenogeneic islets. Transplanted islets in the remodeled spleens showed improved engraftment, neovascularization, and functionality and restored normoglycemia in streptozotocin (STZ)–induced type 1 diabetic models in the mice and macaques, with stable insulin and C-peptide secretion in mice for 90 days and macaques for 28 days. KSiNP injection and islet transplantation into macaque spleens under B-ultrasound guidance were preclinically feasible.
These findings highlight the safety and effectiveness of spleen tissue remodeling in supporting the survival and function of transplanted islets, providing a promising strategy for treating type 1 diabetes mellitus (T1DM)."
Islet transplantation in immunomodulatory nanoparticle–remodeled spleens (no public access)
Human islets grown in the immune-remodeled spleen of macaques.
No comments:
Post a Comment